Villere St Denis J & Co Has Cut Genesee & Wyo (GWR) Stake By $1.30 Million; Dexcom (DXCM) Has 0.97 Sentiment

February 21, 2018 - By Hazel Jackson

DexCom, Inc., a medical device company, together with its subsidiaries, focuses on the design, development, and commercialization of continuous glucose monitoring systems in the United States and internationally. The company has market cap of $4.95 billion. The firm offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers in the hospital for the treatment of patients with and without diabetes. It currently has negative earnings. The Company’s products include DexCom G4 PLATINUM system for continuous use by adults with diabetes; DexCom G4 PLATINUM with Share, a remote monitoring system; and DexCom G5 Mobile, a CGM system that directly communicates to a patientÂ’s mobile and its data can be integrated with DexCom CLARITY, which is a next generation cloud reporting software for personalized, easy-to-understand analysis of trends to improve diabetes management.

Villere St Denis J & Co Llc decreased Genesee & Wyo Inc (GWR) stake by 1.84% reported in 2017Q3 SEC filing. Villere St Denis J & Co Llc sold 17,550 shares as Genesee & Wyo Inc (GWR)’s stock declined 14.44%. The Villere St Denis J & Co Llc holds 938,344 shares with $69.45M value, down from 955,894 last quarter. Genesee & Wyo Inc now has $4.54 billion valuation. The stock increased 0.35% or $0.25 during the last trading session, reaching $72.7. About 22,190 shares traded. Genesee & Wyoming Inc. (NYSE:GWR) has risen 13.88% since February 21, 2017 and is uptrending. It has underperformed by 2.82% the S&P500.

Analysts await Genesee & Wyoming Inc. (NYSE:GWR) to report earnings on May, 1. They expect $0.75 earnings per share, up 41.51% or $0.22 from last year’s $0.53 per share. GWR’s profit will be $46.78 million for 24.23 P/E if the $0.75 EPS becomes a reality. After $0.77 actual earnings per share reported by Genesee & Wyoming Inc. for the previous quarter, Wall Street now forecasts -2.60% negative EPS growth.

Among 13 analysts covering Genesee & Wyoming Inc. (NYSE:GWR), 8 have Buy rating, 0 Sell and 5 Hold. Therefore 62% are positive. Genesee & Wyoming Inc. had 43 analyst reports since August 5, 2015 according to SRatingsIntel. The stock has “Top Pick” rating by RBC Capital Markets on Tuesday, August 4. The rating was maintained by Cowen & Co with “Buy” on Friday, September 29. The company was maintained on Tuesday, October 31 by Cowen & Co. The firm has “Sector Perform” rating given on Friday, April 29 by RBC Capital Markets. Stifel Nicolaus maintained the shares of GWR in report on Tuesday, August 1 with “Hold” rating. The stock of Genesee & Wyoming Inc. (NYSE:GWR) earned “Outperform” rating by Cowen & Co on Monday, November 2. The firm has “Hold” rating by RBC Capital Markets given on Wednesday, April 12. As per Friday, December 4, the company rating was downgraded by Bank of America. The stock of Genesee & Wyoming Inc. (NYSE:GWR) earned “Outperform” rating by RBC Capital Markets on Wednesday, September 2. Bank of America maintained Genesee & Wyoming Inc. (NYSE:GWR) on Friday, February 9 with “Buy” rating.

Villere St Denis J & Co Llc increased Pinnacle Foods Inc Del (NYSE:PF) stake by 16,300 shares to 186,500 valued at $10.66 million in 2017Q3. It also upped Schlumberger Ltd (NYSE:SLB) stake by 10,501 shares and now owns 135,686 shares. Pepsico Inc (NYSE:PEP) was raised too.

Since August 25, 2017, it had 0 buys, and 4 insider sales for $792,534 activity. Walsh Matthew O. also sold $255,250 worth of Genesee & Wyoming Inc. (NYSE:GWR) on Tuesday, August 29. Shares for $275,086 were sold by Brown David A. The insider Fergus Allison M sold 2,546 shares worth $168,443. $93,755 worth of Genesee & Wyoming Inc. (NYSE:GWR) was sold by Liucci Christopher F on Tuesday, August 29. HELLMANN JOHN C also sold $926,918 worth of Genesee & Wyoming Inc. (NYSE:GWR) shares.

Investors sentiment increased to 1.07 in Q3 2017. Its up 0.08, from 0.99 in 2017Q2. It improved, as 27 investors sold GWR shares while 82 reduced holdings. 37 funds opened positions while 80 raised stakes. 58.92 million shares or 1.22% more from 58.21 million shares in 2017Q2 were reported. Sei Co has 0.05% invested in Genesee & Wyoming Inc. (NYSE:GWR). Stifel Fincl invested 0.02% of its portfolio in Genesee & Wyoming Inc. (NYSE:GWR). Amp Cap Limited reported 0.02% in Genesee & Wyoming Inc. (NYSE:GWR). Ameriprise Fincl has 184,895 shares. Royal Bankshares Of Canada accumulated 0% or 26,038 shares. California-based Symphony Asset Limited Liability Co has invested 0.06% in Genesee & Wyoming Inc. (NYSE:GWR). First Wilshire Secs Mngmt stated it has 0.07% of its portfolio in Genesee & Wyoming Inc. (NYSE:GWR). Dimensional Fund Limited Partnership invested in 1.59M shares or 0.05% of the stock. Commonwealth Of Pennsylvania Public School Empls Retrmt invested 0.01% in Genesee & Wyoming Inc. (NYSE:GWR). Landscape Cap Mgmt Ltd Llc invested in 0.04% or 5,087 shares. Scopus Asset Management Lp holds 225,000 shares. Goldman Sachs, a New York-based fund reported 562,368 shares. Riverhead Capital Mngmt Limited Com reported 5,057 shares. Cubist Systematic Strategies Ltd Llc accumulated 0.02% or 4,571 shares. Victory Capital owns 553,649 shares or 0.09% of their US portfolio.

The stock decreased 0.28% or $0.16 during the last trading session, reaching $56.97. About 3,154 shares traded. DexCom, Inc. (DXCM) has risen 9.41% since February 21, 2017 and is uptrending. It has underperformed by 7.29% the S&P500.

Deerfield Management Co holds 3.13% of its portfolio in DexCom, Inc. for 1.42 million shares. Pura Vida Investments Llc owns 120,000 shares or 2.94% of their US portfolio. Moreover, Tirschwell & Loewy Inc has 2% invested in the company for 270,595 shares. The California-based Dafna Capital Management Llc has invested 1.75% in the stock. Sessa Capital Im L.P., a New York-based fund reported 300,000 shares.

Since January 1, 0001, it had 0 buys, and 9 selling transactions for $2.15 million activity.

Ratings analysis reveals 67% of Dexcom’s analysts are positive. Out of 3 Wall Street analysts rating Dexcom, 2 give it “Buy”, 0 “Sell” rating, while 1 recommend “Hold”. The lowest target is $66.0 while the high is $70.0. The stock’s average target of $68 is 19.36% above today’s ($56.97) share price. DXCM was included in 3 notes of analysts from November 2, 2016. Oppenheimer upgraded the shares of DXCM in report on Monday, December 19 to “Outperform” rating. The company was downgraded on Tuesday, January 3 by Morgan Stanley. The stock of DexCom, Inc. (NASDAQ:DXCM) earned “Buy” rating by Canaccord Genuity on Wednesday, November 2.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Hazel Jackson

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: